Enteris BioPharma makes three appointments


Oral dosage formulations specialist also unveils enhancements to Peptelligence oral peptide delivery platform

Enteris BioPharma, a privately held developer of oral dosage formulations, has officially launched its business, operational and development activities.

At the same time, the New Jersey-based firm has unveiled enhancements to its Peptelligence oral peptide delivery platform, which extend the technology to small molecule drugs.

Enteris recently acquired the Peptelligence platform, along with nasal delivery technology and a recombinant manufacturing process for therapeutically relevant peptides, from Unigene Laboratories in New Jersey.

The firm has appointed Brian Zietsman as President and Chief Financial Officer, Nozer Mehta as Chief Scientific Officer and Paul Shields as Vice President of Operations.

‘We are focused on solving challenging formulation issues for our partners using our proprietary, clinically-proven Peptelligence technology in combination with our formulation development and manufacturing expertise,’ said Zietsman. ‘In doing so, we are targeting the myriad therapeutic indications in which physician acceptance and patient compliance can be improved through more convenient and effective medications.’

Peptelligence enables the oral delivery of BCS class II, III and IV compounds in an enteric-coated tablet formulation.

Mehta added: ‘Our goal will be to develop business and scientific initiatives with our partners to apply Peptelligence to currently marketed peptides and small molecules or to those in development, thereby helping patients in areas of unmet need, while increasing the potential effectiveness and marketability of a drug. An elegant formulation solution, Peptelligence utilises a unique multifaceted approach to increase the solubility, stability and absorption of peptides and small molecules in the digestive tract, while reducing variability and food effects.’

Sign up for your free email newsletter

Most recently, Zietsman, Mehta and Shields were Chief Financial Officer, Chief Scientific Officer and VP of Manufacturing Operations, respectively, at Unigene Laboratories.